A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial Abstract #1224
Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Aim(s): To assess the efficacy and safety of EVE+PAS compared to EVE alone in patients (pts) with advanced, progressive pNET.
Materials and methods: We performed a randomized, open-label, phase II study of EVE±PAS in pts with advanced G1/G2 pNET; stratified by prior SSA use, baseline CgA and/or NSE. Primary endpoint was PFS. Secondary endpoints included RECIST-defined tumor response rate, overall survival (OS), and safety.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Matthew H Kulke
Authors: Kulke M H, Ruszniewski P, Van Cutsem E, Valle J, De Herder W, Pavel M, Degtyarev E, Lam D, Salazar R, Borbath I, Fazio N, Lombard-Bohas C, Yao J C
To read results and conclusion, please login ...
Further abstracts you may be interested in
#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model
Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr. Herbert A. Schmid
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3
Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Takuji Okusaka
#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone
Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Bryan A Chan
#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.
Presenting Author: Antongiulio Faggiano